JP7314310B2 - 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用 - Google Patents

眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用 Download PDF

Info

Publication number
JP7314310B2
JP7314310B2 JP2021565942A JP2021565942A JP7314310B2 JP 7314310 B2 JP7314310 B2 JP 7314310B2 JP 2021565942 A JP2021565942 A JP 2021565942A JP 2021565942 A JP2021565942 A JP 2021565942A JP 7314310 B2 JP7314310 B2 JP 7314310B2
Authority
JP
Japan
Prior art keywords
seq
antibody
semaphorin
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021565942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531698A (ja
Inventor
トーマス，レオ
バレット，レイチェル・レベッカ
ボバット，クリスティン・ラウラ
ガネサン，ラクマー
グプタ，プリヤンカー
ハン，フェイ
リウ，ドンメイ
プレストル，ユルゲン
シン，サンジャヤ
ヴェンカタラマニ，サティヤデヴィ
ウー，ヘレン・ハイシャ
ジッペル，ニナ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022531698A publication Critical patent/JP2022531698A/ja
Priority to JP2023114243A priority Critical patent/JP7638332B2/ja
Application granted granted Critical
Publication of JP7314310B2 publication Critical patent/JP7314310B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021565942A 2019-05-09 2020-05-08 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用 Active JP7314310B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023114243A JP7638332B2 (ja) 2019-05-09 2023-07-12 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09
EP19173454.0 2019-05-09
PCT/EP2020/062802 WO2020225400A1 (en) 2019-05-09 2020-05-08 Anti-sema3a antibodies and their uses for treating eye or ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023114243A Division JP7638332B2 (ja) 2019-05-09 2023-07-12 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2022531698A JP2022531698A (ja) 2022-07-08
JP7314310B2 true JP7314310B2 (ja) 2023-07-25

Family

ID=66476463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565942A Active JP7314310B2 (ja) 2019-05-09 2020-05-08 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用
JP2023114243A Active JP7638332B2 (ja) 2019-05-09 2023-07-12 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023114243A Active JP7638332B2 (ja) 2019-05-09 2023-07-12 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用

Country Status (28)

Country Link
US (3) US11267880B2 (enExample)
EP (1) EP3966239A1 (enExample)
JP (2) JP7314310B2 (enExample)
KR (1) KR20220007128A (enExample)
CN (1) CN113795509A (enExample)
AR (1) AR122266A1 (enExample)
AU (1) AU2020267874A1 (enExample)
BR (1) BR112021019854A2 (enExample)
CA (1) CA3137377A1 (enExample)
CL (1) CL2021002795A1 (enExample)
CO (1) CO2021014768A2 (enExample)
CR (1) CR20210559A (enExample)
DO (1) DOP2021000226A (enExample)
EA (1) EA202193038A1 (enExample)
EC (1) ECSP21082527A (enExample)
IL (1) IL287758A (enExample)
JO (1) JOP20210300A1 (enExample)
MA (1) MA55872A (enExample)
MX (1) MX2021013671A (enExample)
MY (1) MY206253A (enExample)
NZ (1) NZ780763A (enExample)
PE (1) PE20220287A1 (enExample)
PH (1) PH12021552776A1 (enExample)
SA (1) SA521430793B1 (enExample)
SG (1) SG11202110842QA (enExample)
TW (1) TWI836069B (enExample)
UA (1) UA129953C2 (enExample)
WO (1) WO2020225400A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023130473A (ja) * 2019-05-09 2023-09-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用
JP2023546461A (ja) * 2020-10-23 2023-11-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 網膜の血栓性疾患の処置のための抗セマフォリン３ａ抗体及びその使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4314047A1 (en) * 2021-03-30 2024-02-07 Bayer Aktiengesellschaft Anti-sema3a antibodies and uses thereof
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014123186A1 (ja) 2013-02-06 2014-08-14 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
JP2016065066A (ja) 2009-11-05 2016-04-28 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
JP2016516003A (ja) 2013-02-21 2016-06-02 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
JP2017527616A (ja) 2014-09-05 2017-09-21 アールエスイーエム，リミティド パートナーシップ 炎症を処置および予防するための組成物および方法
JP2019500889A (ja) 2015-10-27 2019-01-17 サムスン ライフ パブリック ウェルフェア ファウンデーションＳａｍｓｕｎｇ Ｌｉｆｅ Ｐｕｂｌｉｃ Ｗｅｌｆａｒｅ Ｆｏｕｎｄａｔｉｏｎ ヒト及びマウスＳｅｍａ３Ａに交差結合する抗体及びその用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO2013005603A1 (ja) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 結膜におけるアレルギー性炎症の予防及び／又は治療剤
WO2017074013A1 (ko) 2015-10-27 2017-05-04 사회복지법인 삼성생명공익재단 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
AR122266A1 (es) * 2019-05-09 2022-08-31 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016065066A (ja) 2009-11-05 2016-04-28 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2014123186A1 (ja) 2013-02-06 2014-08-14 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
JP2016516003A (ja) 2013-02-21 2016-06-02 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
JP2017527616A (ja) 2014-09-05 2017-09-21 アールエスイーエム，リミティド パートナーシップ 炎症を処置および予防するための組成物および方法
JP2019500889A (ja) 2015-10-27 2019-01-17 サムスン ライフ パブリック ウェルフェア ファウンデーションＳａｍｓｕｎｇ Ｌｉｆｅ Ｐｕｂｌｉｃ Ｗｅｌｆａｒｅ Ｆｏｕｎｄａｔｉｏｎ ヒト及びマウスＳｅｍａ３Ａに交差結合する抗体及びその用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Am J Physiol Cell Physiol, 2009, Vol. 297,pp. C238-C252
InternationalImmunology, 2015, Vol. 27, No. 9, pp. 459-466
J.Biol.Chem., 2002,Vol. 277, No. 51, pp. 49799-49807

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023130473A (ja) * 2019-05-09 2023-09-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用
JP7638332B2 (ja) 2019-05-09 2025-03-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用
JP2023546461A (ja) * 2020-10-23 2023-11-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 網膜の血栓性疾患の処置のための抗セマフォリン３ａ抗体及びその使用

Also Published As

Publication number Publication date
MA55872A (fr) 2022-03-16
DOP2021000226A (enExample) 2021-12-15
US20240336674A1 (en) 2024-10-10
US11267880B2 (en) 2022-03-08
CN113795509A (zh) 2021-12-14
JOP20210300A1 (ar) 2023-01-30
SG11202110842QA (en) 2021-10-28
BR112021019854A2 (pt) 2022-02-15
MY206253A (en) 2024-12-05
IL287758A (en) 2022-01-01
CR20210559A (es) 2021-12-23
UA129953C2 (uk) 2025-09-24
EP3966239A1 (en) 2022-03-16
EA202193038A1 (ru) 2022-03-30
ECSP21082527A (es) 2021-12-30
AR122266A1 (es) 2022-08-31
AU2020267874A1 (en) 2021-10-28
JP7638332B2 (ja) 2025-03-03
NZ780763A (en) 2025-09-26
US20220144929A1 (en) 2022-05-12
SA521430793B1 (ar) 2024-03-28
PH12021552776A1 (en) 2022-09-19
CA3137377A1 (en) 2020-11-12
PE20220287A1 (es) 2022-02-25
CO2021014768A2 (es) 2021-11-19
CL2021002795A1 (es) 2022-08-05
MX2021013671A (es) 2021-12-10
TWI836069B (zh) 2024-03-21
TW202108621A (zh) 2021-03-01
KR20220007128A (ko) 2022-01-18
JP2023130473A (ja) 2023-09-20
WO2020225400A1 (en) 2020-11-12
US20200385446A1 (en) 2020-12-10
JP2022531698A (ja) 2022-07-08

Similar Documents

Publication Publication Date Title
TWI856979B (zh) 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法
JP7638332B2 (ja) 眼又は眼疾患を処置するための抗セマフォリン３ａ抗体及びその使用
US20250243266A1 (en) Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
US20250250330A1 (en) Ang-2/vegf antibodies and uses thereof
US20220363743A1 (en) Anti-angpt2 antibodies
JP7691976B2 (ja) 抗Ｎｒｐ１Ａ抗体及びその眼又は眼部疾患を治療するための使用
EA048015B1 (ru) Антитела против sema3a и их применения для лечения заболеваний глаз
EA049293B1 (ru) АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ
EA046375B1 (ru) Способ лечения воспалительных заболеваний

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230613

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230712

R150 Certificate of patent or registration of utility model

Ref document number: 7314310

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150